CN Patent

CN116867494A — Irak4降解剂和其用途

Assigned to Kemela Medical Co · Expires 2023-10-10 · 3y expired

What this patent protects

本发明涉及一种治疗受试者的自身免疫/自身发炎性疾病及血液恶性病的方法。

USPTO Abstract

本发明涉及一种治疗受试者的自身免疫/自身发炎性疾病及血液恶性病的方法。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN116867494A
Jurisdiction: CN
Classification: —
Expires: 2023-10-10
Drug substance claim: No
Drug product claim: No
Assignee: Kemela Medical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.